Study Group: Urologists who Treat BPH (EU)(?)

This drug only shows that it retards prostate growth, not that it shrinks the gland. Finasteride and dutasteride actually shrink he prostate and much quicker also.  The improvements in symptom scores and flow rates, although statistically significant, will make absolutely no difference in...

This article is too flawed from the outset for it to be used as constructive evidence in the debate as to whether surgery or radiotherapy is better for treatment of prostate cancer.  Its core message is being publishised in the media without even the authors' own warnings as to its applicability...

This is encouraging news in a disease process that is very debilitating and fatal, with huge co-morbidity.  The use of an oral agent is of course a huge step forward.  Although at very early stages, this is a very exciting development.  The introduction of a phase 3...

Trials in prostate cancer almost always suffer by assigning end points (such as reduction in PSA) which do not translate across the board to overall survival.  One of the advantages of trialing drugs/agents in hormone refractory prostate cancer is that the most important endpoint can be assessed,...

There are many established therapies which are currently in use which achieve the exact same result of PSA reduction with much better science behind them.   This drug manifests its activity by decreasing PSA and number of positive biopsies post radiotherapy treatment for prostate cancer. ...